Skip to content

JBIO JBIO Additional Paid-In Capital

Additional Paid-In Capital at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$1.61B+5.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.38B+31.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$838.31M+0.7%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$536.45M+6.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1B+3.7%
Vor Biopharma logo
Vor BiopharmaVOR
$1.22B+120%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's additional paid-in capital?
JBIO (JBIO) reported additional paid-in capital of $511.55M in Q1 2026.
How has JBIO's additional paid-in capital changed year-over-year?
JBIO's additional paid-in capital increased by 64.7% year-over-year, from $310.56M to $511.55M.
What is the long-term trend for JBIO's additional paid-in capital?
Over 5 years (2020 to 2025), JBIO's additional paid-in capital has grown at a 504.1% compound annual growth rate (CAGR), from $63K to $506.77M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.